Targets › TUSC2
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
May function as a tumor suppressor, inhibiting colony formation, causing G1 arrest and ultimately inducing apoptosis in homozygous 3p21.3 120-kb region-deficient cells. (UniProt, O75896)
Open in Phaseline: the race on TUSC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Genprex | quaratusugene ozeplasmid TUSC2 gene therapy - interrupts cell signaling pathways, reestablishes cancer cell death p | TUSC2 | Phase 1 | Small Cell Lung Cancer Extensive Stage; Carcinoma, Non-Small Cell Lung | Dec 2027 |
Small Cell Lung Cancer Extensive Stage (1) Carcinoma, Non-Small Cell Lung (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.